Research
Hormonal
Genetic predisposition to obesity, particularly variants in FTO and MC4R, increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers primarily through its effect on BMI, establishing a causal link between obesity and these comorbidities.
If you have a family history of obesity, recognize that your genetic risk may make you more susceptible to weight gain and related metabolic issues. This doesn't mean you are doomed, but it does mean you should prioritize preventive lifestyle measures (diet, activity) earlier and more consistently than those without such risk factors.
StrongSupportsHIGH confidence
The same approach, when applied to 12 obesity gene variants, confirmed that the genetic predisposition to obesity leads to an increased risk of developing type 2 diabetes, which is completely mediated by its effect on BMI [46]. The FTO genotype has also been used to confirm the findings of observational epidemiology and a causal relationship between BMI increase and altered glucose [47], insulin resistance [48], lipid [47] and blood pressure values [49].
Why this rating
Based on Mendelian randomization studies and large-scale GWAS data cited in the review, providing robust causal evidence.
Source
Genetics of Obesity: What have we Learned?
Hélène Choquet et al. · Current Genomics · 2011
DOI 10.2174/138920211795677895
narrative_reviewCited 232×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High levels of physical activity can blunt the effect of obesity-predisposing genetic variants (specifically FTO) on BMI and obesity risk, reducing the genetic predisposition by approximately 40%.Good
- Genetic variants (e.g., FTO, MC4R) influence the response to obesity treatments, including lifestyle interventions, pharmacotherapy, and bariatric surgery, with some variants predicting poorer weight loss outcomes after certain procedures.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →